Roche (RHHBY) News Today $35.44 +0.15 (+0.43%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartDividendHeadlinesInsider TradesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Neuron23 Announces Usage of Roche's Digital Biomarker and Device in Parkinson's Disease Clinical TrialNovember 19, 2024 | businesswire.comRoche receives CE Mark for Ventana FOLR1 RxDx AssayNovember 19, 2024 | markets.businessinsider.comRoche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay Gets CE Mark In Ovarian Cancer TreatmentNovember 18, 2024 | markets.businessinsider.comRoche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERENovember 18, 2024 | prnewswire.comFlare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in OncologyNovember 12, 2024 | prnewswire.comGenentech terminates agreement for Nykode cancer vaccine programNovember 9, 2024 | markets.businessinsider.comGenentech to present blood disorders data at ASHNovember 7, 2024 | markets.businessinsider.comF. Hoffmann-La Roche Ltd: Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024November 5, 2024 | finanznachrichten.deRoche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024November 5, 2024 | globenewswire.comPredicineCARE™ Liquid Biopsy Assay Featured in NEJM as Pivotal Tool in Roche's Phase III Itovebi Breast Cancer TrialNovember 4, 2024 | globenewswire.comAntibody-Drug Conjugates (ADC) Technology Research and Global Markets Report 2024-2025 & 2029 with Profiles of Leading Players - F. Hoffmann-La Roche.November 4, 2024 | globenewswire.comRoche Holding AG (RHHBY) Virtual Neurology Investor Event Conference TranscriptNovember 2, 2024 | seekingalpha.comRoche announces phase III INAVO120 results were publishedNovember 1, 2024 | markets.businessinsider.comRoche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer's diseaseOctober 31, 2024 | globenewswire.comNew England Journal of Medicine publishes landmark phase III results for Roche's Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancerOctober 31, 2024 | globenewswire.comDyno signs second Roche deal worth over $1BOctober 26, 2024 | bizjournals.comPharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory NewsOctober 25, 2024 | finance.yahoo.comRoche reports Q3 sales growth, driven by strong pharma performance and ActemraOctober 24, 2024 | investing.comUSA News Group: Health and Wellness Industry Embraces Surge in Demand for Weight Loss DrugsOctober 24, 2024 | finanznachrichten.deRoche reports 9M group sales CHF 44.98B vs. CHF 44.05B last yearOctober 24, 2024 | markets.businessinsider.comRoche sees 2024 core EPS growing in high single digit rangeOctober 24, 2024 | markets.businessinsider.comRoche reaffirms 2024 outlook after Q3 beatOctober 24, 2024 | msn.comRoche comes out against clearing takeover of drug manufacturer CatalentOctober 23, 2024 | reuters.comRoche Group Sales In Q3, 9M Rise; Confirms FY24 OutlookOctober 23, 2024 | markets.businessinsider.comRoche Q3 sales advance by forex-adj 9%, beating market viewOctober 23, 2024 | reuters.com[Ad hoc announcement pursuant to Art. 53 LR] Roche's strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine monthsOctober 23, 2024 | globenewswire.comCan Roche Challenge Lilly and Novo in the Weight Loss Market?One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.October 22, 2024 | marketbeat.comGenentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind StudyOctober 20, 2024 | businesswire.comGenentech announces topline one-year results from ELEVATUM studyOctober 20, 2024 | finance.yahoo.comRoche receives FDA approval for Ventana CLDN18 RxDx AssayOctober 20, 2024 | finance.yahoo.comPharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New DrugsOctober 19, 2024 | msn.comRoche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind studyOctober 19, 2024 | finance.yahoo.comELEVATUM Study:Roche' Vabysmo Enhances Vision In Underrepresented Diabetic Macular Edema PopulationsOctober 19, 2024 | markets.businessinsider.comGenentech's Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind StudyOctober 18, 2024 | businesswire.comRoche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind studyOctober 18, 2024 | globenewswire.comRoche receives FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOYOctober 18, 2024 | prnewswire.comJazz Pharma gains on late-stage trial win for cancer drugOctober 17, 2024 | msn.comMajority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech's Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data DemonstrateOctober 14, 2024 | businesswire.comMajority of children with spinal muscular atrophy (SMA) treated with Roche's Evrysdi are able to sit, stand and walk independently, two-year data demonstrateOctober 14, 2024 | globenewswire.comRoche gets FDA approval for Itovebi combo therapy for breast cancerOctober 11, 2024 | seekingalpha.comRoche Gets FDA OK for ItovebiOctober 11, 2024 | marketwatch.comFDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutationOctober 11, 2024 | finance.yahoo.comFDA approves Roche's Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutationOctober 11, 2024 | globenewswire.comFDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA MutationOctober 10, 2024 | finance.yahoo.comThursday's Stock Trades: Palantir, Pfizer, and MoreOctober 10, 2024 | baystreet.caWeight-loss drugs: How much should investors worry about side effects?October 10, 2024 | msn.comRoche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOYOctober 10, 2024 | globenewswire.comRoche CEO: breast cancer pill could be in 10 bln CHF market if trials succeedOctober 9, 2024 | reuters.comSurvey commissioned by Roche shows that HPV infection, which causes 99% of all cervical cancer cases, remains largely misunderstood by the general publicOctober 8, 2024 | prnewswire.comRoche Hldg is Now Oversold (RHHBY)October 6, 2024 | nasdaq.com Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump Wins… But Elon Says Get Ready to Brace (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov RHHBY Media Mentions By Week RHHBY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RHHBY News Sentiment▼-0.330.49▲Average Medical News Sentiment RHHBY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RHHBY Articles This Week▼46▲RHHBY Articles Average Week Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aalberts News Absa Group News Airbus News Airports of Thailand Public News Akbank T.A.S. News Amadeus IT Group News ANA News Asia Broadband News Atlas Copco News Avolta News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:RHHBY) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Roche With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
